Literature DB >> 1995956

Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.

M Connors1, P L Collins, C Y Firestone, B R Murphy.   

Abstract

The ability of recombinant vaccinia viruses that separately encoded 9 of the 10 known respiratory syncytial virus (RSV) proteins to induce resistance to RSV challenge was studied in BALB/c mice. Resistance was examined at two intervals following vaccination to examine early (day 9) as well as late (day 28) immunity. BALB/c mice were inoculated simultaneously by the intranasal and intraperitoneal routes with a recombinant vaccinia virus encoding one of the following RSV proteins: F, G, N, P, SH, M, 1B, 1C, or M2 (22K). A parainfluenza virus type 3 HN protein recombinant (Vac-HN) served as a negative control. One half of the mice were challenged with RSV intranasally on day 9, and the remaining animals were challenged on day 28 postvaccination. Mice previously immunized by infection with RSV, Vac-F, or Vac-G were completely or almost completely resistant to RSV challenge on both days. In contrast, immunization with Vac-HN, -P, -SH, -M, -1B, or -1C did not induce detectable resistance to RSV challenge. Mice previously infected with Vac-M2 or Vac-N exhibited significant but not complete resistance on day 9. However, in both cases resistance had largely waned by day 28 and was detectable only in mice immunized with Vac-M2. These results demonstrate that F and G proteins expressed by recombinant vaccinia viruses are the most effective RSV protective antigens. This study also suggests that RSV vaccines need only contain the F and G glycoproteins, because the immunity conferred by the other proteins is less effective and appears to wane rapidly with time.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1995956      PMCID: PMC239952     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection.

Authors:  P J Openshaw; K Anderson; G W Wertz; B A Askonas
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

2.  Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins.

Authors:  J A Nicholas; K L Rubino; M E Levely; E G Adams; P L Collins
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

3.  Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies.

Authors:  E E Walsh; J J Schlesinger; M W Brandriss
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

4.  Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.

Authors:  B R Murphy; A V Sotnikov; L A Lawrence; S M Banks; G A Prince
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

5.  Aerosol vaccination with a sendai virus temperature-sensitive mutant (HVJ-pB) derived from persistently infected cells.

Authors:  H Iwata; M Tagaya; K Matsumoto; T Miyadai; T Yokochi; Y Kimura
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

6.  Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus.

Authors:  G A Prince; A B Jenson; V G Hemming; B R Murphy; E E Walsh; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

7.  The envelope-associated 22K protein of human respiratory syncytial virus: nucleotide sequence of the mRNA and a related polytranscript.

Authors:  P L Collins; G W Wertz
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

8.  The pathogenesis of respiratory syncytial virus infection in cotton rats.

Authors:  G A Prince; A B Jenson; R L Horswood; E Camargo; R M Chanock
Journal:  Am J Pathol       Date:  1978-12       Impact factor: 4.307

9.  Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats.

Authors:  G A Prince; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

10.  Monoclonal antibodies protect against respiratory syncytial virus infection in mice.

Authors:  G Taylor; E J Stott; M Bew; B F Fernie; P J Cote; A P Collins; M Hughes; J Jebbett
Journal:  Immunology       Date:  1984-05       Impact factor: 7.397

View more
  82 in total

1.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

Review 2.  The Interaction between Respiratory Pathogens and Mucus.

Authors:  Mark Zanin; Pradyumna Baviskar; Robert Webster; Richard Webby
Journal:  Cell Host Microbe       Date:  2016-02-10       Impact factor: 21.023

3.  Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice.

Authors:  Karen A Herd; Suresh Mahalingam; Ian M Mackay; Michael Nissen; Theo P Sloots; Robert W Tindle
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Development of a luciferase immunoprecipitation system assay to detect IgG antibodies against human respiratory syncytial virus nucleoprotein.

Authors:  Sangeeta Kumari; Roberta Lynne Crim; Ashwin Kulkarni; Susette A Audet; Thembi Mdluli; Haruhiko Murata; Judy A Beeler
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

5.  More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Josephine McAuliffe; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

6.  Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.

Authors:  Helene Plotnicky-Gilquin; Dominique Cyblat-Chanal; Jean-Pierre Aubry; Thierry Champion; Alain Beck; Thien Nguyen; Jean-Yves Bonnefoy; Nathalie Corvaïa
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.

Authors:  Junyan Han; Katsuyuki Takeda; Meiqin Wang; Wanjiang Zeng; Yi Jia; Yoshiki Shiraishi; Masakazu Okamoto; Azzeddine Dakhama; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2014-07       Impact factor: 6.914

8.  Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus.

Authors:  L M Haynes; D D Moore; E A Kurt-Jones; R W Finberg; L J Anderson; R A Tripp
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells.

Authors:  A B Kulkarni; H C Morse; J R Bennink; J W Yewdell; B R Murphy
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

10.  Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model.

Authors:  Asunción Mejías; Susana Chávez-Bueno; Ana María Ríos; Jesús Saavedra-Lozano; Mónica Fonseca Aten; Jeanine Hatfield; Payal Kapur; Ana María Gómez; Hasan S Jafri; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.